Alzinova AB (Nasdaq First North: ALZ) has announced a strategic collaboration with Worldwide Clinical Trials (“Worldwide”), a global leader in neuroscience studies, appointing them as the Clinical Research Organisation (CRO) for Alzinova’s upcoming Phase 2 study with ALZ-101.
Hank Riordan, Chief Development Officer of Worldwide Clinical Trials, comments:
“At Worldwide, we are deeply committed to Alzinova’s mission of empowering patients to lead independent and active lives, free from the burdens of Alzheimer’s disease. We are proud to partner with the Alzinova team on the development of ALZ-101, a novel vaccine candidate that holds significant promise as a potentially disease-modifying therapy for patients living with Alzheimer’s disease.”
Read the full press release here.
